Water content comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control relies on predefined specifications rather than a single purity number. A certificate of analysis typically lists the test method, acceptance limit, and measured result for each attribute. Common specifications include appearance, peptide content, water content, counterion identity, and related substances. Limits are set according to the peptide's intended use and the capability of the analytical method. A result outside a limit triggers investigation, not automatic rejection, because method variability and sample handling can affect outcomes.
Sample handling influences measured purity. Lyophilized peptides are hygroscopic and can absorb water, changing weight-based calculations, while repeated freeze-thaw cycles may promote aggregation or degradation. Dissolved samples should be prepared fresh when possible and protected from light and heat. In purity testing, the same handling conditions should apply to standards and samples. Stability-indicating methods are designed to separate degradation products from the parent peptide, though open questions remain about how accelerated stability data predict long-term behavior for every sequence.
Peptide purity testing distinguishes several impurity classes. Related substances include truncated sequences, deletion peptides, and diastereomers formed during synthesis, while residual solvents, counterions, and water are not peptide-related but affect mass balance. Aggregates and oxidation products can arise during storage. Each class requires different analytical approaches, and a complete purity profile combines separation, mass measurement, and orthogonal assays. Reporting only a single percentage can obscure which impurities are present, so the profile should name the methods and limits used.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | ≥95% area by HPLC | Specification depends on intended use. |
| Water content | Karl Fischer titration | Reported as percent by mass. |
| Counterion identity | Ion chromatography or titration | Common counterions include acetate and trifluoroacetate. |
| Related substances | RP-HPLC with UV detection | Reported as individual and total area percent. |
| Typical storage condition | -20 °C, desiccated | Lyophilized powder; protect from moisture. |
=== Transfer RNA (tRNA) is the physical link between RNA and protein === Biochemical fractionation experiments showed that radioactive amino acids were rapidly incorporated into small RNA molecules that remained soluble under conditions where larger RNA-containing particles would precipitate. These molecules were termed soluble (sRNA) and were later renamed transfer RNA (tRNA). Subsequent studies showed that (i) every cell has multiple species of tRNA, each of which is associated with a single specific amino acid, (ii) that there are a matching set of enzymes responsible for linking tRNAs with the correct amino acids, and (iii) that tRNA anticodon sequences form a specific decoding interaction with mRNA codons.
Candesartan is administered clinically as the cyclohexyl 1-hydroxy ethyl carbonate ester, known as candesartan cilexetil. It is a cascading prodrug that is completely metabolised by esterases in the intestinal wall during absorption, releasing the active candesartan moiety. In the first step of the activation process, the carbonate group is hydrolyzed, releasing carbon dioxide. This reaction also produces cyclohexanol, a relatively non-toxic byproduct that contributes to the favorable safety profile of the prodrug. Another side product of the cascading mechanism is acetic acid, derived from the hydrolysis of the O-CH(CH3)- group; like cyclohexanol, it is also non-toxic and poses minimal risk during drug activation. The use of the prodrug form, candesartan cilexetil, enhances the bioavailability of candesartan. However, its absolute bioavailability remains relatively low, ranging from approximately 15% when administered as tablets to 40% as an oral solution. Candesartan has an IC50 of 15 μg/kg. The active form of candesartan is not used directly in clinical practice, as it would require higher dosing and is associated with a less favorable adverse event profile.
However, these salts also interact directly with proteins (which are charged and have strong dipole moments) and may even bind specifically (e.g., phosphate and sulfate binding to ribonuclease A). As a result, these interactions can lead to protein denaturation, the formation of artificial adducts, or the partial dissociation of (metal) cofactors, thus, disrupting the delicate balance between apo- and holometalloproteins. Ions that have a strong salting in effect such as I− and SCN− are strong denaturants, because they salt in the peptide group, and thus, interact much more strongly with the unfolded form of a protein than with its native form. Consequently, they shift the chemical equilibrium of the unfolding reaction towards unfolded protein.
Sources: en.wikipedia.org
CO2 + OH− ⇌ HCO−3 A reaction similar to this is almost instantaneous with carbonic anhydrase. The structure of the active site in carbonic anhydrases is well known from a number of crystal structures. It consists of a zinc ion coordinated by three imidazole nitrogen atoms from three histidine units. The fourth coordination site is occupied by a water molecule. The coordination sphere of the zinc ion is approximately tetrahedral. The positively-charged zinc ion polarizes the coordinated water molecule, and nucleophilic attack by the negatively-charged hydroxide portion on carbon dioxide proceeds rapidly. The catalytic cycle produces the bicarbonate ion and the hydrogen ion as the equilibrium:
Each person carries 2 alleles of each of the 3 class-I genes, (HLA-A, HLA-B and HLA-C), and so can express six different types of MHC-I (see figure). In the class-II locus, each person inherits a pair of HLA-DP genes (DPA1 and DPB1, which encode α and β chains), a couple of genes HLA-DQ (DQA1 and DQB1, for α and β chains), one gene HLA-DRα (DRA1), and one or more genes HLA-DRβ (DRB1 and DRB3, -4 or -5). That means that one heterozygous individual can inherit six or eight functioning class-II alleles, three or more from each parent. The role of DQA2 or DQB2 is not verified. The DRB2, DRB6, DRB7, DRB8 and DRB9 are pseudogenes. The set of alleles that is present in each chromosome is called the MHC haplotype. In humans, each HLA allele is named with a number. For instance, for a given individual, his haplotype might be HLA-A2, HLA-B5, HLA-DR3, etc... Each heterozygous individual will have two MHC haplotypes, one each from the paternal and maternal chromosomes. The MHC genes are highly polymorphic; many different alleles exist in the different individuals inside a population. The polymorphism is so high, in a mixed population (nonendogamic), no two individuals have exactly the same set of MHC molecules, with the exception of identical twins. The polymorphic regions in each allele are located in the region for peptide contact. Of all the peptides that could be displayed by MHC, only a subset will bind strongly enough to any given HLA allele, so by carrying two alleles for each gene, each encoding specificity for unique antigens, a much larger set of peptides can be presented.
=== Pharmacokinetics === It is metabolized mostly by esterases, and almost completely. The metabolites are excreted in urine. Mebeverine exists in two enantiomeric forms. The commercially available product is a racemic mixture of them. A study in rats indicates that the two have different pharmacokinetic profiles. The drug contains the psychoactive drugs moiety such as para-methoxy-N-ethylamphetamine (PMEA) and para-methoxyamphetamine (PMA) within its chemical structure and can form these drugs as minor active metabolites. This can result in false positives for "ecstasy" on drug tests.
Sources: en.wikipedia.org
In 1924, Hahn was elected to full membership of the Prussian Academy of Sciences in Berlin, by a vote of thirty white balls to two black. While still remaining the head of his own department, he became Deputy Director of the KWIC in 1924, and succeeded Alfred Stock as the director in 1928. Meitner became the director of the Physical Radioactivity Division, while Hahn headed the Chemical Radioactivity Division. In the early 1920s, Hahn created a new line of research. Using the "emanation method", which he had recently developed, and the "emanation ability", he founded what became known as "applied radiochemistry" for the researching of general chemical and physical-chemical questions. In 1936 Cornell University Press published a book in English (and later in Russian) titled Applied Radiochemistry, which contained the lectures given by Hahn when he was a visiting professor at Cornell University in Ithaca, New York, in 1933. This publication had a major influence on almost all nuclear chemists and physicists in the United States, the United Kingdom, France, and the Soviet Union during the 1930s and 1940s. Hahn is referred to as the father of nuclear chemistry, which emerged from applied radiochemistry.
parvulus, has been found in wines that have not gone through MLF (meaning malic acid is still present in the wine), but has still had its bouquet altered in a way that enologist have described as "not spoiled" or flaw. Other studies have isolated P. parvulus from wines that have gone through malolactic fermentation without the development of off odors or wine faults.
== Animal models == Current research on synthetic platelets primarily in preclinical phases of clinical trials, relying on animal models to test their safety, efficacy, and hemostatic performance in relevant therapeutic areas. In one study, researchers evaluated the efficacy of platelet-mimicking procoagulant nanoparticles (PPNs) using various animal models. In a mouse model of thrombocytopenia, induced by administering an anti-CD42b antibody to reduce platelet counts, PPNs were introduced and demonstrated a reduction in bleeding comparable to that achieved with syngeneic platelet transfusions. Additionally, in a rat model of acute liver injury and a mouse model of hemorrhagic trauma, treatment with PPNs led to decreased blood loss and improved survival rates compared to control groups receiving saline or control nanoparticles. These findings suggest that PPNs effectively mimic natural platelet functions, enhancing hemostasis in scenarios of significant bleeding.
Letrozole and anastrozole are aromatase inhibitors which have been shown to be superior to tamoxifen for the first-line treatment of breast cancer in postmenopausal women. Exemestane is an irreversible "aromatase inactivator" which is superior to megestrol acetate for treatment of tamoxifen-refractory metastatic breast cancer, and does not appear to have the osteoporosis-promoting side effects of other drugs in this class. Aminoglutethimide inhibits both aromatase and other enzymes critical for steroid hormone synthesis in the adrenal glands. It was formerly used for breast cancer treatment, but has since been replaced by more selective aromatase inhibitors. It can also be used for the treatment of hyperadrenocortical syndromes, such as Cushing's syndrome and hyperaldosteronism in adrenocortical carcinoma.
Sources: en.wikipedia.org
A related substance is a peptide-like impurity that resembles the target sequence, such as a truncated or modified form. It is often reported as individual and total area percent.
Each test measures a different attribute, such as identity, purity, water content, or counterion. Together they give a more complete quality profile than a single purity percentage.
Lyophilized powder is typically stored cold and dry, while solutions are kept cold and used promptly. Repeated freeze-thaw cycles should be avoided because they can change the sample.
It measures the relative ultraviolet absorbance area of peptide peaks, usually at 214 nm. It does not directly measure mass, water, counterions, or co-eluting species.